Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy

Basit Öğe Kaydı
dc.contributor.authorYıldız, İbrahim
dc.contributor.authorBilici, Ahmet
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorÖzer, Leyla
dc.contributor.authorTural, Deniz
dc.contributor.authorKaplan, Mehmet Ali
dc.contributor.authorAkman, Tülay
dc.contributor.authorBayoğlu, İbrahim Vedat
dc.contributor.authorUysal, Mükremin
dc.contributor.authorYıldız, Yaşar
dc.contributor.authorTanrıverdi, Özgür
dc.contributor.authorYazıcı, Ozan
dc.contributor.authorSürmeli, Zeki
dc.contributor.authorTurhal, Nazim Serdar
dc.contributor.authorBavbek, Sevil
dc.contributor.authorSelçukbiricik, Fatih
dc.contributor.authorKoca, Doğan
dc.contributor.authorBaşaran, Mert
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:49:57Z
dc.date.available10.07.201910:49:13
dc.date.available2019-07-10T19:49:57Z
dc.date.issued2018
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionWOS: 000454667200024
dc.descriptionPubMed ID: 28731496
dc.description.abstractBackground: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and methods: Fifty-eight patients from 16 oncology centers for whom complete clinical data were available were retrospectively reviewed. Results: The median age was 57 years (range 30-80). Most patients underwent a nephrectomy (n = 41; 70.7%), were male (n = 42; 72.4%) and had clear-cell (CC) RCC (n = 51; 87.9%). Patients were treated with first-line suni-tinib (n = 45; 77.6%) or pazopanib (n = 13; 22.4%). The median time from the initial RCC diagnosis to the diagnosis of BMs was 9 months. The median time from the first occurrence of metastasis to the development of BMs was 7 months. The median overall survival (OS) of mRCC patients with BMs was 13 months. Time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months; p = 0.001), histological subtype (non-CC; p<0.05) and number of BMs (>2; p<0.05) were significantly associated with OS in multivariate analysis. There were no cases of toxic death. One mRCC patient with BMs (1.7%) experienced treatment-related cerebral necrosis. All other toxicities included those commonly observed with VEGF-TKI therapy. Conclusions: The time from the initial diagnosis of systemic metastasis to the development of BMs (<12 months), a non-CC histological subtype, and a greater number of BMs (>2) were independent risk factors for a poor prognosis.
dc.identifier.citationYıldız, İ., Bilici, A., Karadurmuş, N., Özer, L., Tural, D., Kaplan, M. ... Başaran, M. (2018). Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy. TUMORI J, 104(6), 444-450. https://dx.doi.org/10.5301/tj.5000635
dc.identifier.doi10.5301/tj.5000635
dc.identifier.endpage450
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue6
dc.identifier.scopusqualityN/A
dc.identifier.startpage444
dc.identifier.urihttps://dx.doi.org/10.5301/tj.5000635
dc.identifier.urihttps://hdl.handle.net/20.500.12511/1831
dc.identifier.volume104
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSage Publications Ltd
dc.relation.ispartofTUMORI Jen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/embargoedAccess
dc.subjectBrain Metastasis
dc.subjectPrognostic Factor
dc.subjectRenal Cell Carcinoma
dc.subjectSurvival
dc.subjectTargeted Therapy
dc.titlePrognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Bilici, A..pdf
Boyut:
319.64 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu